Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
Open Access
- 1 May 2021
- journal article
- research article
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (2) , 243-253
Abstract
Objective: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to investigate benefit of aripiprazole augmentation in the treatment of residual symptoms in the patients with partially remitted MDD. Methods: We retrospectively analyzed the 8-week medical records of the patients. The enrolled patients did respond to treatment of antidepressant but were not remitted. The range of 17-item Hamilton Depression Rating Scale (HAMD) total score of the subjects were 8 to 15 points. All patients were currently taking antidepressants when they started aripiprazole. The primary endpoint was the mean change of Clinically Useful Depression Outcome Scale (CUDOS). Secondary endpoint measures were HAMD, Clinical Global Impression-severity (CGI-S) scores, Patient Health Questionnaire-15 (PHQ-15), Beck Anxiety Inventory (BAI), Perceived Deficit Questionnaire-depression (PDQ-D), Sheehan Disability Scale (SDS) and General Health Questionnaire/Quality of Life-12 (GHQ/QL-12). Results: A total of 134 medical records were analyzed. The changes of CUDOS, HAMD, CGI-S, BAI, PHQ-15, PDQ-D, SDS and GHQ/QL-12 from baseline to the endpoint were -7.93, -3.29, -0.80, -4.02, -2.05, -4.35, -4.77 and -2.82, respectively (all p < 0.001). At the endpoint, the newly remitted subjects rate by HAMD score criteria were approximately 46%. Conclusion: Our preliminary findings have presented the effectiveness of aripiprazole augmentation for residual symptoms of partially remitted MDD patients in routine practice. This study assures subsequent well-controlled studies of the possibility of generalizing the above promising outcome in the future.Keywords
Funding Information
- Korea Otsuka Pharmaceutical
This publication has 57 references indexed in Scilit:
- Severity classification on the Hamilton depression rating scaleJournal of Affective Disorders, 2013
- Association Between Severity of Depression and Self-Perceived Cognitive Difficulties Among Full-Time EmployeesThe Primary Care Companion For CNS Disorders, 2013
- Residual Sleep Disturbances in Patients Remitted From Major Depressive Disorder: A 4-Year Naturalistic Follow-up StudySLEEP, 2012
- Four Cases of Chronic Pain That Improved Dramatically Following Low-Dose Aripiprazole AdministrationThe Primary Care Companion For CNS Disorders, 2011
- Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant MedicationJournal of Clinical Psychopharmacology, 2011
- Aripiprazole as Adjunctive Therapy for Patients with Major Depressive DisorderCNS Drugs, 2011
- Treatment Goals of Depressed OutpatientsJournal of Psychiatric Practice, 2010
- Response and remission criteria in major depression – A validation of current practiceJournal of Psychiatric Research, 2010
- Psychometric Properties of the Patient Health Questionnaire-15 (PHQ-15) for Measuring the Somatic Symptoms of Psychiatric OutpatientsPsychosomatics, 2009
- Reliability and validity of the Hamilton Depression Inventory: A paper-and-pencil version of the Hamilton Depression Rating Scale Clinical Interview.Psychological Assessment, 1995